Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-211-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-16"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20110216.11.3-211-000"2
lpv:hasSubsequent	lp_eu:2011-02-16-Speech-3-212-0002
lpv:speaker	lp:João Ferreira2
lpv:spokenAs	member; Delegation to the EU-Former Yugoslav Republic of Macedonia Joint Parliamentary Committee (2009-09-16--2013-02-03)3,3 unknown; Partido Comunista Português (2009-07-14--2014-06-30)3,3 substitute; ENVI (2009-07-16--2012-01-18)3,3 substitute; Delegation for relations with the countries of the Andean Community (2009-09-16--2014-06-30)3,3 member; EUL/NGL (2009-07-14--2012-02-06)3,3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3,3 member; PECH (2009-07-16--2012-01-18)3,3
lpv:translated text	". This is a problem with serious effects on public health and on the economies of the Member States. The falsification of medicinal products and the alarming quantities entering the legal supply chain are worrying issues that need to be duly addressed and combated. It should not be forgotten that medicinal products are only falsified and sold illegally because there are economic reasons that encourage this phenomenon, as the existence of generic medicinal products at prices that people can afford makes falsification less profitable. The report tackles the relevant issue of sales via the Internet, which is part of the legal supply chain. It refers to the importance of raising public awareness to the risks associated with purchasing medicinal products in this manner. We would highlight the importance of strengthening cooperation and coordination between competent national authorities, the European Medicines Agency (EMA) and other international bodies, with a view to exchanging information, enabling increased knowledge and understanding of the phenomenon and, in this way, improving the fight. It should be remembered that such cooperation must also work in other areas, such as pharmacovigilance. Greater transparency is demanded from existing European structures, such as the EMA, with regard to the studies they carry out and their operations. We believe that the compromise reached is a positive step in the essential fight against this problem."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph